Last reviewed · How we verify
NCT05495191
Signal Intensity Gradient in Cerebral Arteries
trial testing Signal intensity gradient in Ischemic Stroke, Acute in 294 participants. Completed in 23 July 2022.
5 May 2022
Quick facts
| Lead sponsor | Chonbuk National University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 294 |
| Start date | 10 May 2021 |
| Primary completion | 5 May 2022 |
| Estimated completion | 23 July 2022 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Signal intensity gradient
Conditions studied
- Ischemic Stroke, Acute — all drugs for Ischemic Stroke, Acute →
Sponsor
Chonbuk National University Hospital
Who can join
18 and older, any sex, with Ischemic Stroke, Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Arterial wall shear stress (WSS) contributes to atherosclerosis from its inception, progression, and disruption of plaque. However, there is no previous study for an association between cerebral artery WSS and clinical outcome in patients with ischemic stroke in lenticulostriate artery. The researchers aimed to investigate whether the signal intensity gradient (SIG) from Time-of-Flight Magnetic Resonance Angiography (TOF MRA) in cerebral arteries, as a surrogate measure of arterial WSS, is associated with clinical outcome, which was determined with modified Rankin Scale (mRS). The patients (n=294) with the lenticulostriate artery infarction were collected in 3 hospitals with variable locations and sizes (Gunsan, Jeonju, and Seoul). For a clinical outcome, National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) were checked serially from the date of admission. The mRS 2 or less at the 7th day or discharge was defined as a favorable outcome. The arterial SIGs were measured concurrently in both internal carotid, anterior/middle/posterior cerebral, vertebral arteries, and basilar artery from TOF MRA on initial diagnosis. The independent association between the clinical outcome and cerebral arterial SIG was analyzed adjusting for all the possible potential confounders.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05495191
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Signal intensity gradient
Trials testing the same drug.
- NCT05450939 — Characteristics of Signal Intensity Gradient in Subarachnoid Hemorrhage After Aneurysmal Rupture · unknown
- NCT04585971 — A Study on Hemodynamic Relationship Including Cerebral Blood Flow Using Phase Contrast and Signal Intensity Gradient of · unknown
Other recruiting trials for Ischemic Stroke, Acute
Currently open trials in the same condition.
- NCT06639360 — Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke · NA · recruiting
- NCT07043686 — Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study · NA · recruiting
- NCT06920303 — Accuracy of Transcranial Colour Coded Duplex in Comparing With CT Angiography · recruiting
- NCT06712004 — A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke · Phase 2 · recruiting
- NCT06726941 — Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia · NA · recruiting
Other Chonbuk National University Hospital trials
Trials by the same sponsor.
- NCT05324800 — the Efficacy and Safety of Curcuma Longa Extract Mixture on Immune Enhancement · NA · unknown
- NCT05450939 — Characteristics of Signal Intensity Gradient in Subarachnoid Hemorrhage After Aneurysmal Rupture · unknown
- NCT05190237 — the Efficacy and Safety of Fermented Soybean(Doenjang Powder) on Intestinal Microflora and Immune Enhancement. · NA · completed
- NCT04940910 — The Efficacy and Safety of Black Rice Bran Extract on Immune Enhancement · NA · unknown
- NCT04930640 — The Efficacy and Safety of SGF200 on Immune Enhancement · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05495191 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chonbuk National University Hospital
- Last refreshed: 10 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05495191.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing